Deutsche Bank AG reaffirmed their buy rating on shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in a research report sent to investors on Monday morning. Deutsche Bank AG currently has a $255.00 price objective on the medical research company’s stock.

Several other equities analysts have also commented on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a hold rating to a sell rating in a research note on Thursday, August 10th. TheStreet lowered Bio-Rad Laboratories from a b rating to a c+ rating in a research note on Thursday, August 3rd. Jefferies Group LLC reaffirmed a buy rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an outperform rating and a $250.00 price target on the stock. Finally, BidaskClub raised Bio-Rad Laboratories from a hold rating to a buy rating in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $240.80.

Shares of Bio-Rad Laboratories (BIO) opened at 233.15 on Monday. Bio-Rad Laboratories has a 1-year low of $154.89 and a 1-year high of $242.79. The stock has a market cap of $6.91 billion, a price-to-earnings ratio of 460.77 and a beta of 0.93. The firm has a 50-day moving average price of $220.74 and a 200-day moving average price of $217.89.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-earns-buy-rating-from-deutsche-bank-ag/1576936.html.

In related news, EVP Michael Crowley sold 700 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 28.29% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Portformulas Corp acquired a new position in Bio-Rad Laboratories during the 2nd quarter worth about $782,000. Dynamic Technology Lab Private Ltd lifted its stake in Bio-Rad Laboratories by 20.2% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 1,618 shares of the medical research company’s stock worth $366,000 after acquiring an additional 272 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Bio-Rad Laboratories by 1.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,229 shares of the medical research company’s stock worth $1,410,000 after acquiring an additional 100 shares in the last quarter. Martin & Co. Inc. TN lifted its stake in Bio-Rad Laboratories by 0.6% during the 2nd quarter. Martin & Co. Inc. TN now owns 6,825 shares of the medical research company’s stock worth $1,545,000 after acquiring an additional 40 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in Bio-Rad Laboratories by 1.2% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,364 shares of the medical research company’s stock worth $1,440,000 after acquiring an additional 78 shares in the last quarter. 62.84% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.